Faheem Hasnain

“These statements are subject to risks and uncertainties that could cause actual results to differ materially please refer to our sec filings in today's press release for a discussion of these risks we undertake no obligation to update these forward-looking statements except as required by law with that i'll turn the…”

“In February, we reported top-line results from Procera, our Phase III study of saralutinib in patients with PAH.”

“We're very excited to provide an update on the significant progress and momentum with Seralutinib, which is an investigational treatment for pulmonary hypertension, including pulmonary arterial hypertension or PAH, and pulmonary hypertension-associated interstitial lung disease, or PH-ILD.”

“2021 was the year of execution for the Gossamer team, despite the challenges that the preceding two years have provided. We at Gossamer are excited and energized to enter 2022 with two upcoming proof-of-concept Phase II readouts in ulcerative colitis and Pulmonary Arterial Hypertension.”

“Thanks, Bryan, and thank you all for joining us today on Gossamer Bio's third quarter earnings and update call. At the end of today's call, we will conduct a question-and-answer session.”